Hydralazine brain cancer research made a stunning breakthrough in 2025. Scientists at the University of Pennsylvania discovered that hydralazine, a 70-year-old blood pressure drug, can dramatically slow the growth of glioblastoma – the most aggressive form of brain cancer.

This cheap, generic medication puts glioblastoma cells into a permanent “sleep mode” called senescence by blocking a critical enzyme known as ADO (2-aminoethanethiol dioxygenase).

How Hydralazine Stops Glioblastoma Dead in Its Tracks

Researchers developed a special version of the drug (HYZyne) that finally revealed its exact mechanism after seven decades of use. Hydralazine brain cancer-fighting power comes from directly shutting down the ADO enzyme that glioblastoma tumors need to survive and multiply.

Key effects when ADO is blocked:

• Blood vessels relax (original hypertension treatment)
• Hydralazine stops glioblastoma cells from dividing
• Cancer cells enter senescence – they stay alive but stop growing for weeks after just one dose

Why This Hydralazine Brain Cancer Discovery Changes Everything

Glioblastoma currently has:

• Average survival of only 12–18 months
• Less than 5% five-year survival rate
• Few effective treatment options

Hydralazine is already FDA-approved, costs pennies per dose, and has an excellent safety record – even in pregnant women with preeclampsia.

Expert Reactions to the Hydralazine Glioblastoma Breakthrough

Leading neurosurgeons are calling this one of the most exciting developments in decades:

“A generic blood pressure pill that can put the deadliest brain cancer to sleep is nothing short of revolutionary.” – Dr. Walavan Sivakumar, Neurosurgery Director

Next Steps: Human Trials Starting Soon

Because hydralazine is already approved and widely available, researchers can skip years of safety testing. Phase I/II clinical trials combining hydralazine with standard glioblastoma treatments are expected to begin in 2026.

Drug Repurposing: The Future of Cancer Treatment

Hydralazine joins a growing list of old drugs finding powerful new cancer-fighting roles:

• Aspirin → colon cancer prevention
• Metformin → multiple cancers
• Propranolol → tumor shrinkage

For the 15,000+ Americans diagnosed with glioblastoma each year, this hydralazine brain cancer breakthrough offers something extremely rare: real, immediate hope using a medicine that’s already in every pharmacy worldwide.